Login / Signup

Risk factors for serious infections in ANCA-associated vasculitis.

Balazs OdlerRegina RiedlPhilipp GaucklerJae Il ShinJohannes LeiererPeter A MerkelWilliam St ClairFernando FervenzaDuvuru GeethaPaul MonachDavid R W JayneRona M SmithAlexander RosenkranzUlrich SpecksJohn H StoneAndreas Kronbichlernull null
Published in: Annals of the rheumatic diseases (2023)
The use of low-dose TMP/SMX is associated with reduced risk of severe infections in patients with AAV treated with either RTX or CYC/AZA. Reduced B cell subpopulations at start of treatment might be a useful correlate of reduced immunocompetence.
Keyphrases
  • low dose
  • high dose
  • early onset
  • gene therapy
  • replacement therapy